MA26601A1 - Derives 2-(purin-9yl)-tetrahydrofurant-3,4-diol . - Google Patents

Derives 2-(purin-9yl)-tetrahydrofurant-3,4-diol .

Info

Publication number
MA26601A1
MA26601A1 MA25443A MA25443A MA26601A1 MA 26601 A1 MA26601 A1 MA 26601A1 MA 25443 A MA25443 A MA 25443A MA 25443 A MA25443 A MA 25443A MA 26601 A1 MA26601 A1 MA 26601A1
Authority
MA
Morocco
Prior art keywords
tetrahydrofurant
purin
diol
derivatives
Prior art date
Application number
MA25443A
Other languages
English (en)
Inventor
Peter Charles Cousins Richard
Cox Brian
Chan Chuen
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9802066.2A external-priority patent/GB9802066D0/en
Priority claimed from GBGB9813528.8A external-priority patent/GB9813528D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA26601A1 publication Critical patent/MA26601A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA25443A 1998-01-31 1999-01-29 Derives 2-(purin-9yl)-tetrahydrofurant-3,4-diol . MA26601A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9802066.2A GB9802066D0 (en) 1998-01-31 1998-01-31 Chemical compounds
GBGB9813528.8A GB9813528D0 (en) 1998-06-23 1998-06-23 Chemical compounds

Publications (1)

Publication Number Publication Date
MA26601A1 true MA26601A1 (fr) 2004-12-20

Family

ID=26313042

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25443A MA26601A1 (fr) 1998-01-31 1999-01-29 Derives 2-(purin-9yl)-tetrahydrofurant-3,4-diol .

Country Status (39)

Country Link
US (1) US6762170B1 (fr)
EP (1) EP1051425B1 (fr)
JP (1) JP2002501928A (fr)
KR (1) KR20010034473A (fr)
CN (1) CN1289338A (fr)
AP (1) AP2000001875A0 (fr)
AR (1) AR014508A1 (fr)
AT (1) ATE226957T1 (fr)
AU (1) AU757183B2 (fr)
BG (1) BG63783B1 (fr)
BR (1) BR9907270A (fr)
CA (1) CA2318278A1 (fr)
CO (1) CO4980872A1 (fr)
DE (1) DE69903708T2 (fr)
DK (1) DK1051425T3 (fr)
EA (1) EA003194B1 (fr)
EE (1) EE200000441A (fr)
ES (1) ES2186330T3 (fr)
GE (1) GEP20022839B (fr)
HK (1) HK1030611A1 (fr)
HR (1) HRP20000511A2 (fr)
HU (1) HUP0101305A3 (fr)
ID (1) ID26326A (fr)
IL (1) IL137042A0 (fr)
IS (1) IS5550A (fr)
MA (1) MA26601A1 (fr)
NO (1) NO20003867D0 (fr)
NZ (1) NZ505452A (fr)
OA (1) OA11447A (fr)
PE (1) PE20000280A1 (fr)
PL (1) PL342670A1 (fr)
PT (1) PT1051425E (fr)
SI (1) SI1051425T1 (fr)
SK (1) SK11192000A3 (fr)
SV (1) SV1999000009A (fr)
TR (1) TR200002218T2 (fr)
TW (1) TW434250B (fr)
WO (1) WO1999038877A2 (fr)
YU (1) YU44900A (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
US6495528B1 (en) * 1998-06-23 2002-12-17 Smithkline Beecham Corporation 2-(Purin -9-yl)-tetrahydrofuran-3,4-diol derivatives
GB9813565D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813540D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813554D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US7427606B2 (en) 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
GB0104555D0 (en) * 2001-02-23 2001-04-11 Glaxo Group Ltd New Therapeutic method
GB2372742A (en) 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
US20040162422A1 (en) * 2001-03-20 2004-08-19 Adrian Hall Chemical compounds
NZ532062A (en) 2001-10-01 2006-09-29 Univ Virginia 2-propynyl adenosine analogues having A2 adenosine recepter agonist activity and compositions thereof to treat inflammatory responses
GB0206655D0 (en) * 2002-03-21 2002-05-01 Glaxo Group Ltd Novel process
GB0206657D0 (en) * 2002-03-21 2002-05-01 Glaxo Group Ltd Novel intermediate and process
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
ATE363907T1 (de) * 2003-12-29 2007-06-15 Can Fite Biopharma Ltd Verfahren zur behandlung von multipler sklerose
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
TWI346109B (en) * 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
WO2006015357A2 (fr) 2004-08-02 2006-02-09 University Of Virginia Patent Foundation Analogues de 2-propynyle adenosine comprenant des groupes 5'-ribose modifies presentant une activite agoniste a2a
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
WO2006028618A1 (fr) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation Analogues d'adenosine de propynyle 2-polycyclique presentant des groupes 5'-ribose modifies presentant une activite agoniste de a2a
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
AR058104A1 (es) 2005-10-21 2008-01-23 Novartis Ag Compuestos organicos
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
PT2322525E (pt) * 2006-04-21 2013-12-26 Novartis Ag Derivados de purina para utilização como agonistas do recetor de adenosina a2a
EP1889846A1 (fr) * 2006-07-13 2008-02-20 Novartis AG Dérivés de purine comme agonistes du recepteur A2a
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Ｐｉ３ｋ脂質キナーゼ阻害剤としてのピラゾロピリミジン
EP2089393A1 (fr) 2006-10-30 2009-08-19 Novartis AG Composés hétérocycliques en tant qu'agents anti-inflammatoires
PL2231642T3 (pl) 2008-01-11 2014-04-30 Novartis Ag Pirymidyny jako inhibitory kinazy
US20110281917A1 (en) 2009-01-29 2011-11-17 Darrin Stuart Substituted Benzimidazoles for the Treatment of Astrocytomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
AU2010283806A1 (en) 2009-08-12 2012-03-01 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
SG178454A1 (en) 2009-08-17 2012-03-29 Intellikine Inc Heterocyclic compounds and uses thereof
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
WO2012107500A1 (fr) 2011-02-10 2012-08-16 Novartis Ag Composés de [1, 2, 4] triazolo [4, 3 -b] pyridazine en tant qu'inhibiteurs de la tyrosine kinase c-met
WO2012116237A2 (fr) 2011-02-23 2012-08-30 Intellikine, Llc Composés hétérocycliques et leurs utilisations
WO2012116217A1 (fr) 2011-02-25 2012-08-30 Irm Llc Composés et compositions en tant qu'inhibiteurs de trk
JP5957526B2 (ja) 2011-09-15 2016-07-27 ノバルティス アーゲー チロシンキナーゼとしての６−置換３−（キノリン−６−イルチオ）−［１，２，４］トリアゾロ［４，３−ａ］ピラジン
WO2013078440A2 (fr) 2011-11-23 2013-05-30 Intellikine, Llc Régimes de traitement améliorés utilisant des inhibiteurs de mtor
CN110507654A (zh) 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
JP2016512835A (ja) 2013-03-15 2016-05-09 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせ及びそれらの使用
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
US9957270B2 (en) 2014-03-13 2018-05-01 Agency For Science, Technology And Research Fused pyrimidine-based hydroxamate derivatives
WO2016011658A1 (fr) 2014-07-25 2016-01-28 Novartis Ag Polythérapie
US10195208B2 (en) 2014-07-31 2019-02-05 Novartis Ag Combination therapy
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE768925A (fr) 1970-06-30 1971-11-03 Takeda Chemical Industries Ltd Derives d'adenosine et procede de preparation
DE2034785A1 (de) 1970-07-14 1972-01-20 Boehnnger Mannheim GmbH, 6800 Mann heim Waldhof Adenosin 5 carbonsäurederivate
US4224438A (en) 1970-07-14 1980-09-23 Boehringer Mannheim Gmbh Adenosine-5'-carboxylic acid amides
CA1019727A (en) 1971-03-18 1977-10-25 Abbott Laboratories Adenosine-5'-carboxylic acid amides
BE789773A (fr) 1971-10-08 1973-04-06 Schering Ag Adenosines n6 -substituees et leur procede de
US3864483A (en) 1972-03-22 1975-02-04 Abbott Lab Adenosine-5{40 -carboxylic acid amides
CA1082695A (fr) 1972-04-10 1980-07-29 Francis E. Fischer Preparation d'adenosine-5'-carboxamides
US3966917A (en) 1974-07-30 1976-06-29 Abbott Laboratories Platelet aggregation inhibitors
US4146715A (en) 1975-08-27 1979-03-27 Burroughs Wellcome Co. 2-amido-9-(2-acyloxyethoxymethyl)hypoxanthines
DE2621470A1 (de) * 1976-05-14 1977-12-01 Pharma Waldhof Gmbh & Co Nucleosidcarbonsaeurenitrile und ihre derivate, und verfahren zu ihrer herstellung
US4167565A (en) 1976-11-08 1979-09-11 Abbott Laboratories Adenosine-5'-carboxamides and method of use
AU8379182A (en) 1981-06-04 1982-12-09 Procter & Gamble Company, The Composition of salicylates and purine derivatives
JPS58167599A (ja) 1982-03-29 1983-10-03 Tanabe Seiyaku Co Ltd アデノシン誘導体及びその製法
JPS58174322A (ja) 1982-04-07 1983-10-13 Tanabe Seiyaku Co Ltd 線溶促進剤
CA1239397A (fr) 1983-08-01 1988-07-19 James A. Bristol Adenosines substituee en position n.sup.6
DE3406533A1 (de) 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
US4496643A (en) 1984-03-23 1985-01-29 Eastman Kodak Company Two-component dry electrostatic developer composition containing onium charge control agent
JPH0655756B2 (ja) 1984-04-18 1994-07-27 ネルソン・リサ−チ・アンド・デベロツプメント・カンパニ− 心臓血管拡張薬としてのｎ−６置換アデノシン誘導体
US5310731A (en) 1984-06-28 1994-05-10 Whitby Research, Inc. N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
US4663313A (en) 1984-10-26 1987-05-05 Warner-Lambert Company N6 -tricyclic adenosines for treating hypertension
AU575438B2 (en) 1984-10-26 1988-07-28 Warner-Lambert Company N6 - substituted deoxyribose analogues of adenosines
US5258380A (en) 1985-06-24 1993-11-02 Janssen Pharmaceutica N.V. (4-piperidinylmethyl and -hetero)purines
US4738954A (en) 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
US4755594A (en) 1986-01-31 1988-07-05 Warner-Lambert Company N6 -substituted adenosines
US5106837A (en) 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
JPH0696534B2 (ja) 1986-04-25 1994-11-30 ヘキストジヤパン株式会社 抗痴呆剤
US4767747A (en) 1986-08-28 1988-08-30 Warner-Lambert Company Method for treating congestive heart failure with N6 -acenaphthyl adenosine
WO1988003147A1 (fr) 1986-10-31 1988-05-05 Warner-Lambert Company Adenosines a substitution n6 selectionees ayant une activite de liaison a2 selective
AU8274187A (en) 1986-10-31 1988-05-25 Warner-Lambert Company Heteroaromatic derivatives of adenosine
HU198950B (en) 1986-12-15 1989-12-28 Sandoz Ag Process for producing new furanuronic acid derivatives and pharmaceutical compositions comprising such compounds
FI880405A (fi) 1987-02-04 1988-08-05 Ciba Geigy Ag Adenosin-5'-karboxamidderivat.
US4968697A (en) 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US4962194A (en) 1987-04-02 1990-10-09 Warner-Lambert Company Method of preparing 51,N6-disubstituted adenosines from inosines
US5219840A (en) 1987-04-06 1993-06-15 Sandoz Ltd. Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
LU87181A1 (fr) 1987-04-06 1988-11-17 Sandoz Sa Nouveaux derives de l'acide furannuronique,leur preparation et leur utilisation comme medicaments
US5021574A (en) 1988-03-03 1991-06-04 Ortho Pharmaceutical Corporation 6-substituted purinyl piperazine derivatives
JPH0725785B2 (ja) 1989-01-11 1995-03-22 日本臓器製薬株式会社 アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
GB8920534D0 (en) 1989-09-11 1989-10-25 Wellcome Found Antiviral compounds
CA2028002A1 (fr) 1989-10-19 1991-04-20 Daniel P. Becker Methode de traitement des troubles de la motilite gastro-intestinale
US5055569A (en) 1989-10-19 1991-10-08 G. D. Searle & Co. N-(6)-substituted adenosine compounds
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
US5140015A (en) 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US5280015A (en) 1990-09-05 1994-01-18 The United States Of America As Represented By The Department Of Health And Human Services 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides
WO1992005177A1 (fr) 1990-09-25 1992-04-02 Rhone-Poulenc Rorer International (Holdings) Inc. Composes possedant des proprietes anti-hypertensives et anti-ischemiques
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
FR2685918B1 (fr) 1992-01-08 1995-06-23 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
FR2687678B1 (fr) 1992-01-31 1995-03-31 Union Pharma Scient Appl Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant.
IT1254915B (it) 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
US5424297A (en) 1992-04-27 1995-06-13 University Of Virginia Alumni Patents Foundation Adenosine dextran conjugates
WO1994002497A1 (fr) 1992-07-15 1994-02-03 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Derives sulfo d'adenosine
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
WO1994018215A1 (fr) 1993-02-03 1994-08-18 Gensia, Inc. Inhibiteurs d'adenosine-kinase comprenant des derives de lyxofuranosyle
US5773423A (en) 1993-07-13 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
US5446046A (en) 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
WO1995018817A1 (fr) 1994-01-07 1995-07-13 Laboratoires Upsa Nouveaux derives de l'adenosine, leurs procedes de preparation, compositions pharmaceutiques les contenant
GB9414193D0 (en) * 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
GB9414208D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
AU3255097A (en) * 1996-07-05 1998-02-02 Novo Nordisk A/S Novel (n)-alkoxyadenine derivatives acting as cytokine inhibitors
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
AU4377397A (en) 1996-10-14 1998-05-11 Novo Nordisk A/S Novel therapeutically active adenosine derivatives
FR2757518B1 (fr) 1996-12-23 1999-06-11 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
CO4990969A1 (es) 1998-02-14 2000-12-26 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
US6495528B1 (en) 1998-06-23 2002-12-17 Smithkline Beecham Corporation 2-(Purin -9-yl)-tetrahydrofuran-3,4-diol derivatives
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
NO20003867L (no) 2000-07-28
SI1051425T1 (en) 2003-04-30
IS5550A (is) 2000-06-27
AP2000001875A0 (en) 2000-09-30
CA2318278A1 (fr) 1999-08-05
NO20003867D0 (no) 2000-07-28
ATE226957T1 (de) 2002-11-15
HUP0101305A3 (en) 2002-08-28
CO4980872A1 (es) 2000-11-27
ID26326A (id) 2000-12-14
AU2719799A (en) 1999-08-16
HUP0101305A2 (hu) 2002-04-29
IL137042A0 (en) 2001-06-14
BG63783B1 (bg) 2002-12-29
DE69903708D1 (de) 2002-12-05
EA200000723A1 (ru) 2001-04-23
WO1999038877A3 (fr) 1999-09-30
DK1051425T3 (da) 2003-03-03
BR9907270A (pt) 2000-10-24
PT1051425E (pt) 2003-03-31
PL342670A1 (en) 2001-07-02
SV1999000009A (es) 2000-09-05
EA003194B1 (ru) 2003-02-27
JP2002501928A (ja) 2002-01-22
BG104729A (en) 2001-04-30
CN1289338A (zh) 2001-03-28
TW434250B (en) 2001-05-16
EP1051425A2 (fr) 2000-11-15
AU757183B2 (en) 2003-02-06
AR014508A1 (es) 2001-02-28
EE200000441A (et) 2001-12-17
KR20010034473A (ko) 2001-04-25
HK1030611A1 (en) 2001-05-11
YU44900A (sh) 2003-01-31
NZ505452A (en) 2003-01-31
OA11447A (en) 2004-04-29
GEP20022839B (en) 2002-11-25
DE69903708T2 (de) 2003-07-03
HRP20000511A2 (en) 2000-12-31
EP1051425B1 (fr) 2002-10-30
US6762170B1 (en) 2004-07-13
WO1999038877A2 (fr) 1999-08-05
PE20000280A1 (es) 2000-03-28
ES2186330T3 (es) 2003-05-01
SK11192000A3 (sk) 2001-06-11
TR200002218T2 (tr) 2000-12-21

Similar Documents

Publication Publication Date Title
MA26601A1 (fr) Derives 2-(purin-9yl)-tetrahydrofurant-3,4-diol .
ID29609A (id) Turunan 2-(purin-9-il)-tetrahidrofuran-3,4-diol
ID28219A (id) Turunan 2-(purin-9-il) -tetrahidrofuran-3,4-diol
DE69716468D1 (de) 2-(purin-9-)-tetrahydrofuran-3,4-diol-derivate
ATE435861T1 (de) 12,13-cyclopropan-epothilonderivate
TR200000520A3 (tr) 4-Fenil-piridin türevleri.
CU23053A3 (es) 1,2,3,4-tetrahidroquinlinas 2-sustituidas 4-amino sustituidas
DZ3159A1 (fr) Derives de purine.
MA26794A1 (fr) Derives de 5-phenyl-pyrimidine.
IT1320120B1 (it) 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-0-tolil-piridin-3-il) -isobutirrammide.
TR199802765A3 (tr) Tiyazol türevleri.
AR028357A1 (es) 4-bencil-1-[2-(4-hidroxi-fenoxi)-etil]-piperidin-3,4-diol
MA26793A1 (fr) Derives de 4-phenyl-pyrimidine.
EE04089B1 (et) 1,3,4-oksadiasolooni derivaadid
DE60025958D1 (de) 14,15-beta-methylen substituierte androgene
BR9916188B1 (pt) derivados de cromano.
DE69906149D1 (de) 4,5-azolo-oxindole
NL1013652A1 (nl) Piperazinonderivaten.
IT1319526B1 (it) Macchina i.s.
IT1319528B1 (it) Macchina i.s.
ES1040916Y (es) Microterminal perfeccionado.
FR2790466B1 (fr) Machine i.s.
ES1039438Y (es) Expositor-expendedor perfeccionado.
ES1039265Y (es) Rocodromo perfeccionado.
IT1311300B1 (it) Camicia per cilindro.